Treatment of Mucocutaneous Langerhans Cell Histiocytosis: Isolated Cutaneous Nodule of the Skin or Oral Mucosal Lesion

This protocol addresses mucocutaneous Langerhans cell histiocytosis presenting as a single, localised lesion — either an isolated cutaneous nodule of the skin or an oral mucosal lesion — without systemic involvement.

Clinical Scenario

The patient presents with unifocal mucocutaneous LCH: an isolated nodule of the skin or an isolated oral mucosal lesion. Such lesions are typically completely resectable and generally do not require systemic therapy.

Treatment Approach (partial)

Management is guided by local therapy, with the selection of specific intervention determined by lesion site and characteristics — in some cases, observation alone is the appropriate initial approach.

The complete structured regimen, including all options and clinical decision points, is available via the link below.

Treatment Goal

Complete anatomic resolution of the lesion with a durable response.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/blood.2021014343

Isolated skin nodules, lymph nodes, oral mucosal lesions, and isolated polyps of the gastrointestinal tract are usually completely resectable and require no further therapy.

For unifocal LCH (except DI), observation or local therapies such as surgical excision, intralesional steroids, or radiation are recommended as first-line treatments.

Depending on the location, intralesional corticosteroid therapy (eg, methylprednisone or triamcinolone) or, especially in the case of an accompanying soft tissue component, radiation therapy (eg, 10-20 Gy) may offer an excellent and durable response.

View source ↗